MarketCap
Facebook
X
Telegram
Interpace Biosciences Total Shareholders Equity | IDXG
Annual Total Shareholders Equity Interpace Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.4 M | -2.22 M | -55.5 M | -58.1 M | -42.4 M | -29.1 M | -4.48 M | 15.4 M | 39.9 M | 39.9 M | 13 M | 20.1 M | 32.5 M | 35.6 M | 59.5 M | 69.5 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 69.5 M | -58.1 M | 9.75 M |
Quarterly Total Shareholders Equity Interpace Biosciences
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.22 M | 23.1 M | -55.5 M | -298 K | -1.21 M | -582 K | -2.22 M | -50.5 M | -52.3 M | -54.8 M | -61.7 M | -62.7 M | -62.2 M | -62.5 M | -63.1 M | -61.6 M | -48 M | -44.3 M | -42.4 M | -38.6 M | -35.8 M | -32.9 M | -29.1 M | -29.1 M | -29.1 M | -29.1 M | -4.48 M | -4.48 M | -4.48 M | -4.48 M | 15.4 M | 32.9 M | 32.9 M | 32.9 M | 22.9 M | 39.9 M | 39.9 M | 39.9 M | -10.1 M | 6.53 M | 6.53 M | 6.53 M | 10.1 M | 13 M | 13 M | 13 M | 19.4 M | 20.1 M | 20.1 M | 20.1 M | 32.5 M | 32.5 M | 32.5 M | 32.5 M | 35.6 M | 35.6 M | 35.6 M | 35.6 M | 59.5 M | 59.5 M | 59.5 M | 59.5 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 59.5 M | -63.1 M | -659 K |
Total Shareholders Equity of other stocks in the Diagnostics research industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
VolitionRx Limited
VNRX
|
-34.2 M | $ 0.2 | 3.39 % | $ 25.2 M |  Singapore |
 |
Waters Corporation
WAT
|
2.56 B | $ 458.04 | 1.06 % | $ 27.3 B |  USA |
 |
Exagen
XGN
|
17.4 M | $ 5.79 | -23.82 % | $ 125 M | USA |
 |
Guardant Health
GH
|
-99.3 M | $ 151.28 | -1.4 % | $ 19 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.62 B | $ 366.98 | 1.02 % | $ 30.5 B | USA |
 |
IQVIA Holdings
IQV
|
6.5 B | $ 271.72 | 2.59 % | $ 46.7 B | USA |
 |
Quotient Limited
QTNT
|
-144 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
119 M | - | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
102 M | - | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
3.5 B | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K |  Israel |
 |
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
-7.85 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
5.13 M | - | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
368 M | - | - | $ 1.49 B | USA |
 |
Celcuity
CELC
|
101 M | $ 66.73 | 3.9 % | $ 3.12 B | USA |
 |
DexCom
DXCM
|
2.75 B | $ 79.42 | -5.97 % | $ 31 B | USA |
 |
Agilent Technologies
A
|
6.74 B | $ 175.14 | 1.97 % | $ 49.7 B | USA |
 |
Castle Biosciences
CSTL
|
471 M | $ 32.49 | -4.99 % | $ 942 M | USA |
 |
Anixa Biosciences
ANIX
|
15.2 M | $ 3.16 | 4.29 % | $ 103 K | USA |
 |
Biodesix
BDSX
|
-2.46 M | $ 8.51 | -57.13 % | $ 64.3 M | USA |
 |
BioNano Genomics
BNGO
|
44.4 M | $ 1.15 | 4.54 % | $ 6.26 M | USA |
 |
Bioventus
BVS
|
184 M | $ 10.61 | -0.66 % | $ 707 M | USA |
 |
Fulgent Genetics
FLGT
|
1.11 B | $ 23.68 | 26.9 % | $ 729 M | USA |
 |
CareDx, Inc
CDNA
|
303 M | $ 78.47 | 2.8 % | $ 4.18 B | USA |
 |
Biomerica
BMRA
|
2.63 M | $ 1.61 | -1.55 % | $ 4.69 M | USA |
 |
ICON Public Limited Company
ICLR
|
9.19 B | $ 204.67 | 1.5 % | $ 16.1 B |  Irlanda |
 |
Co-Diagnostics
CODX
|
20.6 M | $ 0.25 | -8.24 % | $ 333 K | USA |
 |
Burning Rock Biotech Limited
BNR
|
535 M | $ 13.2 | -0.38 % | $ 139 M |  China |
 |
DarioHealth Corp.
DRIO
|
67.9 M | $ 2.4 | -11.93 % | $ 9.56 M | Israel |
 |
Myriad Genetics
MYGN
|
368 M | $ 5.97 | -5.17 % | $ 553 M | USA |
 |
ENDRA Life Sciences
NDRA
|
2.26 M | $ 4.73 | -5.49 % | $ 3.72 M | USA |
 |
NeoGenomics
NEO
|
837 M | $ 16.85 | 2.18 % | $ 2.16 B | USA |
 |
OPKO Health
OPK
|
1.27 B | $ 1.72 | -1.71 % | $ 1.29 B | USA |
 |
Pacific Biosciences of California
PACB
|
5.35 M | $ 2.3 | -5.35 % | $ 690 M | USA |
 |
Neogen Corporation
NEOG
|
2.09 B | $ 11.75 | 0.6 % | $ 2.56 B | USA |
 |
Precipio
PRPO
|
14.6 M | $ 18.95 | 2.02 % | $ 30.4 M | USA |
 |
Personalis
PSNL
|
261 M | $ 15.76 | 1.32 % | $ 1.41 B | USA |
 |
Sotera Health Company
SHC
|
606 M | $ 16.01 | 0.88 % | $ 4.55 B | USA |
|
Centogene N.V.
CNTG
|
-25.3 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
1.83 M | - | - | $ 7.1 B |  Australia |